Four Simple Blood Markers Could Flag Deadly Bacteremia in Cancer Patients Within Hours

When a patient with cancer arrives at the emergency department with a fever, clinicians face one of the most consequential diagnostic gambits in acute medicine. Fever in a person with a solid tumor can signal anything from a benign viral infection to bloodstream invasion by virulent bacteria, and the difference between the two can be measured in hours. Blood cultures, the diagnostic gold standard, take a day or more to yield results, while physicians must decide almost immediately whether to admit the patient, start empiric antibiotics, or reserve intensive treatment for those truly at risk. A new study published in BMC Infectious Diseases by researchers at Yonsei University College of Medicine in Seoul offers a strikingly simple answer to this dilemma: a four-variable prediction model built from routine blood tests and vital signs that appears to identify bacteremia with remarkable accuracy.

The research team, led by Chaeryoung Park, Dongryul Ko, biostatistician Yun Ho Roh, and corresponding author Jin-Ho Beom, conducted a retrospective analysis of adult patients with solid tumors who presented with fever to the emergency department of a tertiary academic hospital between January and December 2024. From this cohort, 466 febrile presentations were included in the final analysis. Blood cultures confirmed bacteremia in 82 of these cases, a prevalence of 17.6 percent. That figure alone underscores the scale of the clinical problem: roughly one in six febrile cancer patients arriving at the emergency department was carrying bacteria in their bloodstream, yet their early symptoms were frequently indistinguishable from those of patients with far less dangerous conditions.

The methodological heart of the study lies in how the team distilled a large field of candidate predictors into a parsimonious model. The researchers began with a broad panel of potential markers, including white blood cell count, absolute neutrophil count, C-reactive protein, erythrocyte sedimentation rate, the delta neutrophil index, red cell distribution width, procalcitonin, blood pressure measurements, and numerous other laboratory and clinical variables. To avoid the pitfalls of overfitting that plague many small clinical prediction studies, they applied least absolute shrinkage and selection operator regression, commonly known as LASSO, a statistical technique that penalizes model complexity and drives the coefficients of uninformative variables to zero. This was followed by conventional multivariable logistic regression to refine the final set of predictors and estimate their independent contributions.

What emerged from this process was a model of elegant economy. Just four variables carried essentially all of the predictive signal: serum procalcitonin, pulse rate, the neutrophil-to-lymphocyte ratio, and serum albumin. Each of these markers tells a different part of the story of invasive bacterial infection. Procalcitonin, a peptide precursor of the hormone calcitonin, rises sharply and specifically in response to systemic bacterial challenge, making it one of the most widely studied biomarkers of sepsis. Pulse rate reflects the hemodynamic stress that circulating bacterial toxins and inflammatory cytokines impose on the cardiovascular system. The neutrophil-to-lymphocyte ratio, calculated simply by dividing two counts from a standard complete blood count, captures the relative balance of the innate immune response, which expands neutrophils during bacterial invasion, against the lymphocyte compartment, which is often depleted in acutely infected and physiologically stressed patients. Albumin, meanwhile, falls as vascular permeability increases and the liver shifts its synthetic output toward acute-phase proteins, serving as a quiet barometer of systemic inflammation and nutritional reserve.

The performance statistics reported for this four-marker combination are, on their face, exceptional. The model achieved an area under the receiver operating characteristic curve, or AUC, of 0.948, a value that implies near-perfect separation between bacteremic and non-bacteremic patients when the model’s probability threshold is swept across its full range. Critically, the researchers did not rely on a single optimistic estimate. They subjected the model to ten-fold cross-validation, a resampling procedure in which the dataset is repeatedly partitioned into training and testing subsets, and the cross-validated AUC remained essentially unchanged at 0.947. This stability between apparent and cross-validated performance is a reassuring sign that the model has not merely memorized the quirks of this particular cohort but has captured a genuine biological signal.

Perhaps most telling is the comparison with procalcitonin alone. Procalcitonin is already the best-established single biomarker for bacterial infection in febrile patients, and in this cohort it achieved an AUC of 0.922 on its own, a strong result by any conventional standard. Yet the four-variable model still improved meaningfully upon it. The addition of pulse rate, neutrophil-to-lymphocyte ratio, and albumin contributed information that procalcitonin cannot supply, likely because these markers reflect complementary dimensions of host physiology, including cardiac response, immune cell dynamics, and protein metabolism, that a single inflammatory peptide cannot capture. At the optimal cutoff, the combined model achieved a sensitivity of 0.819 and a specificity of 0.923, meaning it correctly identified roughly 82 percent of true bacteremia cases while correctly clearing more than 92 percent of patients without bloodstream infection.

Discrimination, however, is only half of what a prediction model must demonstrate. A model can rank patients correctly yet produce probability estimates that are systematically too high or too low, which would mislead clinicians who rely on the absolute numbers. To address this, the team performed calibration assessment using the cross-validated data. The calibration intercept was −0.144 and the slope was 0.913, values close to the ideal of zero and one respectively. In practical terms, this means the predicted probabilities tracked the observed frequencies of bacteremia closely across the risk spectrum, neither inflating risk for low-probability patients nor understating it for those in danger. The researchers also conducted decision curve analysis, a technique that evaluates the net clinical benefit of a model across a range of decision thresholds, weighing the harms of unnecessary antibiotics and admissions against the dangers of missed infection.

The clinical implications of such a tool, if its performance holds up, are considerable. Emergency physicians currently operate under guidelines that push most febrile cancer patients toward broad-spectrum empiric antibiotics and hospital admission, a strategy that is safe but expensive, contributes to antimicrobial resistance, and consumes scarce inpatient capacity. A validated risk score could help triage the substantial minority of patients whose fever stems from non-bacterial causes, allowing earlier discharge or targeted oral therapy, while concentrating rapid diagnostic workup and empiric treatment on those at genuinely elevated risk. Because all four components of the model are already measured in virtually every febrile patient, the score could be computed automatically within the electronic medical record, requiring no additional blood draws, no specialized assays beyond standard procalcitonin, and no waiting period.

The authors are appropriately measured about the limits of their work. This was a single-center, retrospective study conducted at one tertiary academic hospital in Seoul, and the model has undergone internal validation only. Retrospective designs are vulnerable to selection bias and missing data, and a model trained on one institution’s patient mix, antibiotic practices, and laboratory platforms may not transfer cleanly to other settings. The researchers explicitly state that independent external validation and prospective evaluation of clinical utility are required before the model can be recommended for routine clinical implementation. History offers many examples of prediction models that performed brilliantly in derivation cohorts and faded under external scrutiny, which is why the field has converged on staged validation as a prerequisite for clinical adoption.

Nevertheless, the study represents a compelling step toward precision triage in oncologic emergencies. Its strength lies not in exotic artificial intelligence or proprietary algorithms but in disciplined statistical methodology applied to information that emergency departments already generate every day. If external validation in diverse patient populations confirms the Seoul team’s findings, the result could be a bedside rule that separates, within minutes of arrival, the febrile cancer patient who needs immediate broad-spectrum antibiotics and intensive monitoring from the one whose fever can be pursued more leisurely. For a patient population in which every hour of delayed treatment compounds mortality risk, and for health systems straining under the weight of unnecessary admissions, that would be a genuinely transformative advance in the emergency care of people living with cancer.

Subject of Research: Prediction of bacteremia in febrile patients with solid tumors in the emergency department

Article Title: A simplified and clinically applicable prediction model for early identification of bacteremia in febrile patients with solid tumors in the emergency department

Article References: Park, C., Ko, D., Roh, Y. H., & Beom, J.-H. (2026). A simplified and clinically applicable prediction model for early identification of bacteremia in febrile patients with solid tumors in the emergency department. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14584-w

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14584-w

Keywords: bacteremia, solid tumors, fever, emergency department, procalcitonin, neutrophil-to-lymphocyte ratio, albumin, prediction model, LASSO regression, sepsis, biomarkers, risk stratification